Reliability and validity of the Japanese version of the Support Team 
Assessment Schedule (STAS-J)

Miyashita, Mitsunori; Matoba, Kazuko; Sasahara, Tomoyo; Kizawa, Yoshiyuki; Maruguchi, Misae; Abé, Mayumi; Kawa, Masako; Shima, Yasuo

doi:10.1017/s1478951504040507

Cited by 86 publications

(59 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Before the treatment, she had high body mass index (BMI) of 44.2 kg/m 2 and no evidence of micro-and macrovascular disturbances and no symptoms of duodenal bulb and gastric ulcers. After changing the oral DPP-4 inhibitor to the subcutaneous injections of 10 µg/ day exenatide (Byetta®, AstraZeneca, Japan) twice daily for T2D, vomiting developed gradually, and she had that the maximum degree of vomiting was 8 points on STAS-J (where 0 is no vomiting and 10 is maximally strong vomiting) [3]. Therefore, we tried to examine the exact cause using gastroscopy.…”

Section: Methodsmentioning

confidence: 99%

Vomiting as Common Adverse Event of Exenatide: A Case of Diabetic Patient with Type 2 and Duodenal Bulb and Gastric Ulcers who Showed Severe Vomiting Increased Gradually after Exenatide Injections

Kamoi¹,

Sasaki²

2015

Int J Clin Case Stud

View full text Add to dashboard Cite

Background: Although exenatide is a valuable option of treatments for type 2 diabetes (T2DM) in obese patients, mild to moderate nausea or vomiting in a usual dose of administration is most common. The adverse event usually decreases with time. Methods and Results: A case of 58-year-old female with T2DM and gastric ulcers is reported. Before treatment with exenatide, she had hemoglobin A1c (NGSP) 7.8% and had received oral miglitol, metformin and DPP-4 inhibitor for T2DM, oral α-blocker and telmisartan for hypertension and oral pitavastatin for dyslipidemia. Before the treatment, she had high body mass index of 44.2 kg/m 2 , but no evidence of micro-and macrovascular disturbances and no symptoms of duodenal bulb and gastric ulcers. After twice daily subcutaneous injections of 10 µg/day exenatide, vomiting developed gradually. We tried to examine exact causes using endoscopy. She was diagnosed with duodenal bulb and gastric ulcers with Helicobacter pylori. She received bactericides drugs. After then, the bacteria were eradicated and vomiting gradually disappeared and she was re-treated with the same dosing schedule of exenatide and had a good control.

show abstract

Section: Methodsmentioning

confidence: 99%

Vomiting as Common Adverse Event of Exenatide: A Case of Diabetic Patient with Type 2 and Duodenal Bulb and Gastric Ulcers who Showed Severe Vomiting Increased Gradually after Exenatide Injections

Kamoi¹,

Sasaki²

2015

Int J Clin Case Stud

View full text Add to dashboard Cite

show abstract

“…[22][23][24][25][26] The Japanese version of the Support Team Assessment Schedule (STAS-J) was developed in 2003. 21 The STAS-J consists of 9 assessment items:…”

Section: Methodsmentioning

confidence: 99%

The Evaluation of the Relationship Between the Level of Disclosure of Cancer in Terminally Ill Patients With Cancer and the Quality of Terminal Care in These Patients and Their Families Using the Support Team Assessment Schedule

Nakajima¹,

Hata

Onishi

et al. 2012

Am J Hosp Palliat Care

View full text Add to dashboard Cite

show abstract

“…The Japanese version of the Support Team Assessment Schedule (STAS-J) score was used as the dyspnea scale [11]. Information regarding the day of the patient's last meal and of the final conversation, adverse events, and interruptions or discontinuation of oxygen therapy were collected from the clinical records.…”

Section: Outcome Measuresmentioning

confidence: 99%

Efficacy and Tolerability of High-Flow Nasal Cannula Oxygen Therapy for Hypoxemic Respiratory Failure in Patients with Interstitial Lung Disease with Do-Not-Intubate Orders: A Retrospective Single-Center Study

et al. 2018

View full text Add to dashboard Cite

Background: High-flow nasal cannula (HFNC) oxygen therapy may provide effective respiratory management of hypoxemic respiratory failure in patients with interstitial lung disease (ILD) with a do-not-intubate (DNI) order. Objectives: The aim was to assess the efficacy and tolerability of HFNC for these patients. Methods: We retrospectively reviewed the records of patients requesting a DNI order for hypoxemic respiratory failure associated with ILD, comparing treatment with HFNC and noninvasive positive pressure ventilation (NPPV). Outcomes measured were 30-day survival, in-hospital mortality, temporary interruption and discontinuation of the treatment at the patient’s request, adverse events, oral intake, and communication ability at the end of life. Results: A total of 84 patients (HFNC, n = 54; NPPV, n = 30) were analyzed. Neither 30-day survival (HFNC 31.5% vs. NPPV 30.0%; p = 0.86) nor in-hospital mortality (HFNC 79.6% vs. NPPV 83.3%; p = 0.78) differed significantly. The temporary interruption and discontinuation rates were significantly lower in the HFNC group than in the NPPV group (3.7 vs. 23.3%; p = 0.009 and 0 vs. 10%; p = 0.043, respectively), and that group had significantly fewer adverse events. Among patients who died in the hospital, those treated with HFNC had significantly better oral intake and ability to converse until just before death. Conclusion: HFNC had a survival rate equivalent to that of NPPV and was better tolerated by patients with hypoxemic respiratory failure associated with ILD who had a DNI order. HFNC allowed patients to eat and converse until just before death, suggesting that HFNC in these patients is a reasonable palliative treatment.

show abstract

Reliability and validity of the Japanese version of the Support Team Assessment Schedule (STAS-J)

Abstract: Although this research was conducted under methodologically limited conditions, we concluded that the STAS-J is a reliable tool and its validity is acceptable. The STAS-J should become a valuable tool, not only for daily clinical use, but also for research.

Cited by 86 publications

References 18 publications

Vomiting as Common Adverse Event of Exenatide: A Case of Diabetic Patient with Type 2 and Duodenal Bulb and Gastric Ulcers who Showed Severe Vomiting Increased Gradually after Exenatide Injections

Vomiting as Common Adverse Event of Exenatide: A Case of Diabetic Patient with Type 2 and Duodenal Bulb and Gastric Ulcers who Showed Severe Vomiting Increased Gradually after Exenatide Injections

The Evaluation of the Relationship Between the Level of Disclosure of Cancer in Terminally Ill Patients With Cancer and the Quality of Terminal Care in These Patients and Their Families Using the Support Team Assessment Schedule

Efficacy and Tolerability of High-Flow Nasal Cannula Oxygen Therapy for Hypoxemic Respiratory Failure in Patients with Interstitial Lung Disease with Do-Not-Intubate Orders: A Retrospective Single-Center Study

Contact Info

Product

Resources

About